Genetics and biomarkers in personalisation of lung cancer treatment.

Abstract excerpt

Non-small-cell lung cancer is often diagnosed at the metastatic stage, with median survival of just 1 year. The identification of driver mutations in the epidermal growth factor receptor (EGFR) as the primary oncogenic event in a subset of lung adenocarcinomas led to a model of targeted treatment and genetic profiling of the disease. EGFR tyrosine kinase inhibitors confer remission in 60% of patients, but...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Apoptosis
• Share to Biomarkers, Tumor
• Share to Carcinoma, Non-Small-Cell Lung